The deal – financial terms of which were not disclosed – will see Intrexon generate strains of micro-organisms for production, fermentation and purification processes. Johnson Matthey will take charge of scale-up and commercialisation.
Johnson Matthey CEO Robert MacLeod said: "Peptides are an important class of therapeutic agents and JM is pleased to be collaborating with the Intrexon team in using their innovative biologically-based technologies to access these technically challenging APIs.
"Through their strain engineering capabilities, we believe there is significant potential for more efficient production of these important compounds."